Topics

Pfizer gets U.S. approval for $225,000 a year heart drug

02:53 EDT 6 May 2019 | Reuters

The U.S. Food and Drug Administration on Monday approved Pfizer Inc's drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Original Article: Pfizer gets U.S. approval for $225,000 a year heart drug

NEXT ARTICLE

More From BioPortfolio on "Pfizer gets U.S. approval for $225,000 a year heart drug"

Quick Search

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...